Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib monotherapy vs combination therapy in moderate-to-severe rheumatoid arthritis
ChiCTR2400081010Phase 4Not yet recruiting
- Sponsor
- The University of Hong Kong-Shenzhen Hospital
- Start
- Feb 2024
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of baricitinib in rheumatoid arthritis (RA) (2 arms), sponsored by The University of Hong Kong-Shenzhen Hospital. Primary endpoints: DAS-28, CDAI and 2 more. Planned start Feb 2024; status: not yet recruiting.
02
Drugs
baricitinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on ChiCTR2400081010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400081010.